Companies Silo Pharma, Inc.
Silo Pharma (SILO): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Silo Pharma, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $630,051FY2024
- $521,750FY2025
CEO total pay was $521,750 in fiscal 2025, down from $630,051 in fiscal 2024.
FY2025: salary $350,000 · bonus $0 · stock awards $0 · option awards $83,782
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Eric Weisblum | $350,000 | $0 | $0 | $83,782 | $0 | $0 | $87,968 | $521,750 |
| Chief Executive Officer (1) | ||||||||
| Daniel Ryweck | 60,000 | 0 | 0 | 20,946 | 0 | 0 | 20,548 | 101,494 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Eric Weisblum | $521,750 | $630,051 | — | ↓ −108,301 |
| Daniel Ryweck | 101,494 | 88,600 | — | ↑ +12,894 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | — |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Daniel Ryweck | Option | 3,333 | 6.43 | — |
| Eric Weisblum | Option | 13,333 | 6.43 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Wayne LinsleyIndependent | $45,000 | $0 | $20,946 | $0 | $0 | $65,946 |
| Dr. Kevin MuñozIndependent · Audit · Compensation · Nominating and Corporate Governance | 25,000 | 0 | 20,946 | 0 | 0 | 45,946 |
| Jeff PavelIndependent | 25,000 | 0 | 20,946 | 0 | 0 | 45,946 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $95,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $95,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Silo Pharma as a peer
Companies that benchmark against SILO
The list of companies that name SILO as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Silo Pharma, Inc. | 2025 | Eric Weisblum | $350,000 | $0 | $83,782 | $0 | $521,750 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (8 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Eric Weisblum. DEF 14A, filed 2026-06-30. Section “Executive Compensation”. As printed: 521,750. View filing ↗
- Section 01, Daniel Ryweck. DEF 14A, filed 2026-06-30. Section “Executive Compensation”. As printed: 101,494. View filing ↗
- Section 08, Wayne Linsley. DEF 14A, filed 2026-06-30. Section “Director Compensation”. As printed: 65,946. View filing ↗
- Section 08, Dr. Kevin Muñoz. DEF 14A, filed 2026-06-30. Section “Director Compensation”. As printed: 45,946. View filing ↗
- Section 08, Jeff Pavel. DEF 14A, filed 2026-06-30. Section “Director Compensation”. As printed: 45,946. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 95,000 + equity 0 + all other 0 = 95,000, summed across the director compensation table rows.
- Silo Pharma, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-06-30. CEO total compensation as printed in Silo Pharma, Inc.'s own proxy. As printed: 521,750. View filing ↗